Phase 3CompletedINTERVENTIONAL
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)
ClinicalTrials.gov · NCT00866658 · Registry updated: 2016-10-11
- Condition / research focus
- Diabetes Mellitus, Type 2
- Sponsor
- Sanofi
- Countries with listed sites
- Japan · Philippines · South Korea · Taiwan
- Registry dates and results
- Start: 2009-03. Completion: 2010-06 (may be estimated). Results are posted in this registry.
Products and interventions (5)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Lixisenatide (AVE0010) (drug)
- Placebo (drug)
- Pen auto-injector (device) — also listed as: OptiClik®
- Sulfonylurea (drug)
- Basal Insulin (drug)
Where the study takes place — 4 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.